| ROS1阳性的非小细胞肺癌的检测及靶向治疗进展 |
| |
| 引用本文： | 张瑞锋,张 奇,刘林林.ROS1阳性的非小细胞肺癌的检测及靶向治疗进展[J].现代肿瘤医学,2021,0(21):3851-3854. |
| |
| 作者姓名： | 张瑞锋 张 奇 刘林林 |
| |
| 作者单位： | 吉林大学第二医院放疗科,吉林 长春 130041 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81773523）;国家自然科学基金（编号:81773523）;吉林省科技厅项目（编号:20190101020JH） |
| |
| 摘 要： | ROS1融合基因是非小细胞肺癌（non-small cell lung cancer，NSCLC）靶向治疗的又一潜力靶点，随着相应靶向药物的使用，ROS1阳性的NSCLC患者生存期明显改善。越来越多针对ROS1融合基因的治疗药物面世，让这类患者有更多的选择。但持续性用药后的获得性耐药问题仍无法避免。本文就ROS1融合基因的检测方法、靶向治疗情况及耐药的机制和策略进行综述。
|
| 关 键 词： | 非小细胞肺癌 ROS1融合基因 基因检测 靶向治疗 耐药 |
Detection and targeted therapies of ROS1-positive non-small cell lung cancer |
| |
| ZHANG Ruifeng,ZHANG Qi,LIU Linlin.Detection and targeted therapies of ROS1-positive non-small cell lung cancer[J].Journal of Modern Oncology,2021,0(21):3851-3854. |
| |
| Authors: | ZHANG Ruifeng ZHANG Qi LIU Linlin |
| |
| Institution: | Department of Radiation Oncology，the Second Affiliated Hospital of Jilin University，Jilin Changchun 130041,China. |
| |
| Abstract: | ROS1 fusion gene is a potential target of targeted therapy for non-small cell lung cancer(NSCLC).With the use of targeted drugs,the survival of ROS1-positive NSCLC patients has been significantly improved.More and more drugs targeting ROS1 fusion gene have been developed,providing more choices for such patients.However,the problem of acquired drug resistance after persistent drug use is still unavoidable.The review has summarized the methods of ROS1 fusion gene detection,targeted therapy and drug resistance mechanisms and strategies. |
| |
| Keywords: | non-small-cell lung cancer ROS1 fusion gene genetic testing targeted therapy drug resistance |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
| 点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
